 |
|
|||||||||||||||||||||||||||||||||
| [发表评论] [本类其他产品] [本类其他供应商] [收藏] | ||||||||||||||||||||||||||||||||||
| 销售商： 广东固康生物科技有限公司 | 查看该公司所有产品 >> |
通用名称：乳腺肿瘤标志（CA 15-3）检测试剂盒（酶联免疫法）
英文名称：CA 15-3 ELISA
【预期用途】
CA15-3 ELISA试剂盒用于定量测定人血清或血浆中的癌抗原CA15-3浓度。。仅供科研使用，不用于体外诊断。
【背景知识】
乳腺癌是当今发达国家妇女最常见的威胁生命的恶性病变，每年约有180000例新诊断病例。这些新诊断的患者中大约有一半是淋巴结阴性，然而这些病例中有30%进展为转移性疾病。
有许多肿瘤标志物可以帮助临床医生识别和诊断哪些乳腺癌患者会有更具侵袭性的疾病。这些标记物包括雌激素和孕激素受体、DNA倍体和S期百分比、表皮生长因子受体、HER-2/新癌基因、p53肿瘤抑制基因、组织蛋白酶D、增殖标记物和CA15-3。CA15-3在监测患者术后复发方面最为有效，尤其是在转移性疾病病例中。96%的局部和全身复发患者的CA15-3升高，这可用于比放射学和临床标准更早地预测复发。血清CA15-3升高25%与癌的进展相关。血清CA15-3降低50%与治疗反应有关。CA15-3在早期检测乳腺癌复发方面比CEA更敏感。联合CA125、CA15-3在卵巢癌复发的早期检测中是有用的。结肠、肺和肝肿瘤中的CA15-3水平也升高。
【包装规格】
96T/盒
样本量：25µl
保存温度：2-8℃
参考文献：
1. Aziz DC, Peter JB. DNA ploidy and cell-cycle analysis. Tools for assessment of cancer prognosis. J Clin Pathol 1991;5:422-38.
2. Clark GM, Dressler LG, Owens MA, Dounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989;320:627-33.
3. Elledge RM, McGuire WL. Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. Annu Rev Med 1993;44:201-10.
4. Foekens JA, Rio C, Seguin P, et al. Prediction of relapse and survival in breast cancer patients by pS2 protein. Cancer Res 1990; 50-3832-7.
5. Isola J, Visakorp T, Holli K, Kallionieml D. Association of p53 expression with other prognostic factors and long term survival in node-negative breast cancer. J Cell Biochem 1992;(Suppl 16D):101.
6. Kute TE, Shao ZM, Snugg NK, Long RT, Russell GB, Case LD. Cathepsin D as a prognostic indicator for nodenegative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 1992;52-198-203.
7. McGuire WL, Tandon AK, Allred D, Chamnes GC, Clark GM. How to use prognostic factors in axillary node negative breast cancer patients. J Natl Cancer Inst 1990;82:1006-7.
8. Nicholson S, Richard J, Sainsbury C, et al. Epidermal growth factor receptor (EGFr): results of a 6 year follow up study in operable breast cancer with emphasis on the node-negative subgroup. Br J Cancer 1991;63:146-50.
9. Somerville JE, Clarke LA, Biggart JD. C-erb B-2 overexpression and histological type of in-situ and invasive breast carcinoma. J Clin Pathol 1992;45-16-20.
